Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrointestinal Microbiome in Metastatic Melanoma Treated With Immunotherapy
NCT07428252Active, not recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab, nivolumab and ipilimumab in melanoma (2 arms), sponsored by Institute of Oncology Ljubljana. Primary endpoint: Objective Treatment Response According to irRECIST up to 28 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07428252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428252.